[ad_1]
Gilead is betting on the transformational innovation, a concept that goes beyond investing in research, because it also involves finding solutions to unresolved medical needs. Gilead can boast of having transformed the history of HIV – transforming a deadly disease into a chronic – hepatitis C – afflicted in 95.5% of patients – and exploring areas such as l & # 39; Oncology for the purpose of healing.
The Spanish subsidiary of the company, in accordance with the strategy of the US multinational, also puts a fundamental part of its efforts in the service of research, and more specifically research in our country, as explained CF María Río, Executive Director of Gilead Spain. "We have the firm determination to bet on Spain," he adds. Thus, the subsidiary has invested more than 100 million euros in R & D over the past five years and celebrated last week the sixth edition of its Scholarships for Biomedical Research (see information below), to which he has allocated an investment of nearly 5 million euros. Rio recalls that during these six years, a total of 416 research projects were presented, of which 106 out of 13 autonomous communities were selected.
In addition, in 2018, the Company launched two new scholarship programs for projects in the areas of diagnosis and early referral of HIV and HCV patients. This year's call will have a budget of 300,000 euros for 10 projects to fight HIV and hepatitis C.
Another example of commitment to Spain and "value-creating research" is reflected in agreement with the Spanish biotech company Aelix, specializing in the discovery and development of HIV immunotherapies. As part of this collaboration, the two companies will conduct a clinical study called AELIX-003, which will evaluate the safety and efficacy of a therapeutic regimen consisting of a therapeutic vaccine and a TLR7 receptor agonist in patients infected with HIV. The goal is that this vaccine fulfills a dual function: on the one hand, activate the expression of HIV in the body and, on the other hand, activate the immune response for the Elimination of the virus.
"There is no precedent for Gilead for such an agreement in Spain, and we are proud that the company has chosen the subsidiary, which speaks volumes about its bet on the country and research, not only internal, but also collaborative ".
More R & D
In addition, Gilead is going on at the present time 50 clinical trials in SpainThe goal is to convert the subsidiary into one of the first for the multinational in number of clinical trials.
At its traditional strongholds, HIV and liver disease support the company's strategic decision in favor of oncology as well as important research areas in areas such as non-alcoholic steatohepatitis (NASH) and inflammation.
In any case, "No other company owns Gilead's HIV portfolio – with six available treatment regimens based on triple therapy and single tablet and HCV ", for which he launched four drugs in four years.
"In all areas, our great ambition is healing, the best example of transformational innovation and contribution to the sustainability of the system." Gilead achieved this goal in hepatitis C ", where we are already facing the real possibility, unimaginable five years ago, to eliminate hepatitis. The data reveal that the yield of Gilead's curative treatments is multiplied by three to five times the required investment. "
This ambition also has an impact on the group's work on HIV. "We have managed to classify a disease that has caused death, but we are not satisfied with it and we want to cure it, as in the case of HCV."
In Oncology, "Gilead has made a huge commitment to leading cell therapy." We are writing a new chapter to transform this disease, "starting with an already approved CAR-T in the US and in the European Union for diffuse large B-cell lymphoma and primary large B-cell mediastinal lymphoma. In addition, he has 30 tests in various indications. In this sense, its main research focuses on the treatment of haematological tumors; with T cells with a cellular receptor (TCR) genetically modified for solid tumors and with BET protein inhibitors.
Inflammation and Nash
The new areas in which Gilead works are non-alcoholic steatohepatitis (NASH), a pathology "still poorly known but which represents a significant medical need" and for which three programs are under development: inhibitor of ASK1 which improves inflammation and reduces fibrosis; a Inhibitor of acetyl-CoA-carboxylase, which decreases the production of de novo fatty acids and increases the beta-oxidation of fatty acids, and a FXR agonist, which controls the synthesis of bile acids and has the effect of reducing insulin resistance.
Finally, in inflammation, oral administration compounds capable of block common signaling pathways to more than one cytokine for its application to different inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis and other indications 4.
The 6th Gilead Awards for Biomedical Research 2018 has recognized 21 projects in the areas of HIV, liver disease and hemato-oncology, evaluated and selected by the Carlos III Health Institute (ISCIII). ). The scholarship program, held last week in Madrid, also enjoys the support of leading scientific societies for HIV, liver disease, hematology and hemotherapy. For the announcement of this year, 900,000 euros have been allocated, for a total of 4.8 million euros for the six editions, making it one of the major research events in our country. During these years, 106 projects from 13 different regions were funded. "This initiative is an example of our commitment to research, but also the capacity of the Spanish centers and the research talent that exists in our country, which is widespread in the Spanish public system," says María Río. During the ceremony, a special tribute to the Sandoval Center in Madrid was also organized to highlight the work of this public center in the prevention, detection and treatment of STDs since its inauguration in 1928. Among the other achievements of this clinic of reference in Spain, it was pointed out that the largest follow-up carried out in Europe vis-à-vis couples with an HIV-positive member, also called serodiscordant.
Award Gilead Scholarships.
Source link
